General Resources / Legal Resources / Medical Resources / Briefing Papers / State Activity    
Hospital Closures / Preventable Tragedies / Press Room / Search Our Site / Home

Psychosocial Treatment Compliance in Schizophrenia.

 

Lysaker PH; Bell MD; Milstein R; Bryson G & Beam Goulet J. Insight and

Psychiatry, Vol. 57, November 1994.

RELEVANCE FOR EARLY INTERVENTION

Unlike most studies of insight in the chronic mentally ill, this study evaluated patients when stabilized and enrolled in an outpatient work rehabilitation program. Patients with schizophrenia and schizoaffective disorder with poor insight had very poor adherence to the psychosocial treatment they had agreed to participate in despite a stated desire to work. Poorer insight was also correlated with lower scores on a test of frontal lobe function and with poorer performance on tests of other cognitive functions. The authors conclude that individuals with schizophrenia and poor insight have more problems remaining in a course of treatment regardless of whether it is pharmacologic or a psychosocial treatment they had expressed a desire to participate in. These data, like that of Young et. al., and Kasapis and colleagues, suggest that it is a mental defect that leads to lack of adherence with both pharmacologic and psychosocial treatments.


general resources | legal resources | medical resources | briefing papers | state activity   
hospital closures | preventable tragedies | press room | search | home

FootnoteImage2.jpg (1088 bytes)
Treatment Advocacy Center

The contents of TAC's website are copyrighted by the Treatment Advocacy Center unless otherwise indicated. All rights reserved and content may be reproduced, downloaded, disseminated, or transferred, for single use, or by nonprofit organizations for educational purposes only, if correct attribution is made. TAC is an I.R.C. § 501(c)(3) tax-exempt corporation. Donations are appreciated and are eligible for the charitable contribution deduction under the provisions of I.R.C. § 170. Please note that TAC does not accept funding from pharmaceutical companies or entities involved in the sale, marketing, or distribution of such products.

Treatment Advocacy Center (TAC), 200 N. Glebe Road, Suite 730, Arlington, VA 22203
703 294 6001/6002 (phone) | 703 294 6010 (fax) | www.treatmentadvocacycenter.org (website)
info@treatmentadvocacycenter.org (general email) | press@treatmentadvocacycenter.org (press contact)
webmaster@treatmentadvocacycenter.org (webmaster)